KRAS and non-small cell lung carcinoma: Inspired by the accelerated approval of Sotorasib for the treatment of KRASG12C mutant NSCLC, an upsurge in the development of KRAS inhibitors has spawned many new cutting-edge strategies, such as fragment-based screening, macromolecular inhibitors, PROTACs, genetic targeting and antibodies targeting covalent inhibitor based neoepitopes.